130 related articles for article (PubMed ID: 17925894)
1. Molecule of the month. Temsirolimus.
Drug News Perspect; 2007; 20(6):406. PubMed ID: 17925894
[No Abstract] [Full Text] [Related]
2. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
4. Neuroendocrine tumors: nursing implications for oral targeted agents and patient management: Part II.
Jacobs C
Clin J Oncol Nurs; 2009 Apr; 13(2):149-53. PubMed ID: 19349261
[No Abstract] [Full Text] [Related]
5. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Huang JJ; Lin TY
Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
[TBL] [Abstract][Full Text] [Related]
6. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
Jafri M; Douis H; Porfiri E
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
[No Abstract] [Full Text] [Related]
7. Temsirolimus for advanced renal cell carcinoma.
Figlin RA
Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
[No Abstract] [Full Text] [Related]
8. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
Bhatia S; Thompson JA
Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
10. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
11. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
Mounier N; Vignot S; Spano JP
Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
[TBL] [Abstract][Full Text] [Related]
12. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
13. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus in the treatment of advanced renal cell carcinoma.
Gore ME
Ann Oncol; 2007 Jul; 18 Suppl 9():ix87-8. PubMed ID: 17631601
[No Abstract] [Full Text] [Related]
15. New mTOR inhibitor for renal cell cancer.
Wilkes GM
Oncology (Williston Park); 2009 Jul; 23(8 Suppl):54-6. PubMed ID: 19860046
[No Abstract] [Full Text] [Related]
16. Clinical development of temsirolimus, a novel mTOR inhibitor, for treatment of advanced malignancies.
Dancey JE
Semin Oncol; 2009 Dec; 36 Suppl 3():S1-2. PubMed ID: 19963095
[No Abstract] [Full Text] [Related]
17. Temsirolimus.
Stock C; Zaccagnini M; Schulze M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2010; 184():189-97. PubMed ID: 20072839
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin as a target in hematological malignancies.
Abdel-Karim IA; Giles FJ
Curr Probl Cancer; 2008; 32(4):161-77. PubMed ID: 18655914
[No Abstract] [Full Text] [Related]
19. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
Paterson C; Jones RJ
Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
[No Abstract] [Full Text] [Related]
20. Temsirolimus, an inhibitor of mammalian target of rapamycin.
Rini BI
Clin Cancer Res; 2008 Mar; 14(5):1286-90. PubMed ID: 18316545
[No Abstract] [Full Text] [Related]
[Next] [New Search]